CaraAngelottaMD

PubMed

• 1 citations
  Emerging Forensic Implications of the Artificial Intelligence Revolution.
  Grabb, D., Angelotta, C.> ;The Journal of the American Academy of Psychiatry and the Law. 2023 Dec 1
• 7 citations
  The frequency of pregnancy recognition across the gestational spectrum and its consequences in the United States.
  Katie Watson, Cara Angelotta> ;Perspectives on Sexual and Reproductive Health. 2022 Jun 1
• 2 citations
  Strategies Mitigating the Impact of the COVID-19 Pandemic on Incarcerated Populations.
  Lauren K. Robinson, Reuben Heyman-Kantor, Cara Angelotta> ;American Journal of Public Health. 2020 Jul 8
• 11 citations
  Treating Depression during Pregnancy: Are We Asking the Right Questions?
  Cara Angelotta, Katherine L. Wisner> ;Birth Defects Research. 2017 Jul 17
• 17 citations
  Criminal Charges for Child Harm from Substance Use in Pregnancy.
  Cara Angelotta, Paul S. Appelbaum> ;The Journal of the American Academy of Psychiatry and the Law. 2017 Jun 1
• 23 citations
  Criminalizing substance use in pregnancy: misplaced priorities
  Katrina Hui, Cara Angelotta, Carl E. Fisher> ;Addiction. 2017 Jul 1
• 68 citations
  A Moral or Medical Problem? The Relationship between Legal Penalties and Treatment Practices for Opioid Use Disorders in Pregnant Women.
  Cara Angelotta, Carol J. Weiss, John W. Angelotta, Richard A. Friedman> ;Women's Health Issues. 2016 Nov 1
• 12 citations
  Defining and refining self-harm: a historical perspective on nonsuicidal self-injury.
  Cara Angelotta> ;The Journal of Nervous and Mental Disease. 2015 Feb 1
• 9 citations
  The Sound and the Fury: Financial Conflicts of Interest in Oncology
  Benjamin Djulbegovic, Cara Angelotta, Kjersti E. Knox> ;Journal of Clinical Oncology. 2007 Aug 20
• 11 citations
  Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia
  Cara Angelotta, June M. McKoy, Mark James Fisher, C. G. Buffie, K. Barfi, Glenn Ramsey, L. Frohlich> ;Vox Sanguinis. 2007 Aug 1
• 34 citations
  Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and phar...
  , , , , , , , , , , , , , , , , , , , > ;Archives of Internal Medicine. 2007 May 28
• 8 citations
  Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.
  Cara C. Tigue, Cara Angelotta, June M. McKoy, Beatrice J. Edwards> ;Seminars in Thrombosis and Hemostasis. 2007 Jun 1
• 128 citations
  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project
  June M. McKoy, Cara Angelotta, Martin S. Tallman, Martha Wadleigh, Andrew M. Evens, Timothy M. Kuzel, Steve Trifilio, Dennis W. Raisch, Jonathan Kell, Daniel J. DeAnge...> ;Leukemia Research. 2007 May 1
• 121 citations
  Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
  Cara Angelotta, Paul R. Yarnold, Andrew M. Evens, Jeffrey A. Zonder, Dennis W. Raisch, Paul G. Richardson> ;JAMA. 2006 Dec 6
• 104 citations
  Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events an...
  Andrew M. Evens, Leslie A. Andritsos, Lakshmi Balasubramanian, Mark Mai, Matthew J. Fisher, Timothy M. Kuzel, Cara Angelotta, June M. McKoy, Julie M. Vose, Philip J. B...> ;British Journal of Haematology. 2006 Dec 1
• 10 citations
  When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective?
  Jared R. Adams, Cara Angelotta> ;Journal of Clinical Oncology. 2006 Jul 1
• Black box warning on lenalidomide-associated venous thromboembolism (VTE) in off-label setting: A preemptive and unusual safety initiative.
  Angelotta C, Lurie AJ, Yarnold PR, Singhal S, Mehta J, Lyons EA, Bennett CL> ;J. Clin. Oncol.. 2006-06-20
• Complementary systems: Quality and timeliness of passive vs. active adverse event reporting and regulatory vs. peer-reviewed adverse drug reaction (ADR) dissemination.
  Bennett CL, Angelotta C, Lurie AJ, Lyons EA, Yarnold PR, Raisch DW> ;J. Clin. Oncol.. 2006-06-20
• Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise?
  Lurie AJ, Djulbegovic B, Nebeker JR, Angelotta C, Gordon LI, Raisch DW, Yarnold PR, Carson KR, McKoy JM, Bennett CL> ;J. Clin. Oncol.. 2006-06-20
• Join now to see all